Welcome to our dedicated page for IONIS PHARMACEUTICALS SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IONIS PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IONIS PHARMACEUTICALS's regulatory disclosures and financial reporting.
Ionis Pharmaceuticals (IONS) announced pivotal Phase 3 success for olezarsen in severe hypertriglyceridemia. The CORE and CORE2 studies met the primary endpoint, with olezarsen delivering a placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months, sustained through 12 months. Olezarsen also achieved a highly statistically significant 85% reduction in adjudicated acute pancreatitis events, and 86% of treated patients reached triglyceride levels below 500 mg/dL.
Safety and tolerability were favorable: adverse events were balanced across arms, serious adverse events were less frequent than placebo, and injection-site reactions were the most common events. At 80 mg, asymptomatic liver enzyme elevations ≥3x ULN occurred in 7% vs 2% on placebo, with no Hy’s law cases and events generally resolving on treatment. Results were presented at the American Heart Association Scientific Sessions and published in NEJM. Ionis plans to submit a supplemental new drug application by year-end and expects a PDUFA target action date in 2026.
Ionis Pharmaceuticals (IONS) filed a Form 4 reporting an insider sale. EVP, Corp and Development Ops Brian Birchler sold 8,000 shares of common stock on 11/06/2025 under a pre-arranged Rule 10b5-1 trading plan adopted on August 12, 2024. The transaction was reported as a sale at a weighted average price of $76.1724, with individual trades executed between $76.00 and $76.32.
Following this transaction, Birchler beneficially owns 48,826 shares directly. The filing notes that detailed trade-by-trade pricing information within the range is available upon request.
Ionis Pharmaceuticals (IONS) executive Richard S. Geary, EVP and Chief Development Officer, reported option exercises and related sales on November 5–6, 2025 under a Rule 10b5-1 trading plan adopted May 6, 2025.
He exercised non‑qualified stock options at $56.78 and $60.89 and sold the corresponding shares in multiple transactions at weighted average prices of $75.01, $76.0972, and $75.421 (with ranges disclosed in footnotes). Individual trades included 800 and 801 shares on November 5, and 14,738 and 18,300 shares on November 6. Following these transactions, Geary beneficially owns 59,657 shares directly.
Ionis Pharmaceuticals (IONS) executive Richard S. Geary filed an amended Form 4 to correct share amounts. On 11/03/2025, he exercised stock options for 775 shares at $60.89 and 905 shares at $56.78, then sold 775 and 905 common shares at a $75.054 weighted average price, with trades ranging from $75.00 to $75.25.
Following these transactions, Geary beneficially owned 59,657 common shares directly. The amendment states it corrects the amounts reported in Column 4.
Ionis Pharmaceuticals (IONS): Director stock transactions disclosed. Director Joseph H. Wender reported open-market sales executed under a Rule 10b5-1 trading plan adopted on December 26, 2024. On 10/30/2025, the trust sold 2,484 shares at a weighted average price of $72.19, 8,341 shares at $73.16, and 5,975 shares at $73.85. On 10/31/2025, it sold 11,200 shares at a weighted average price of $75.1586.
Following these transactions, 64,035 shares were beneficially owned indirectly by a trust. The filing notes the reported prices are weighted averages from multiple trades within disclosed ranges, and detailed trade breakdowns are available upon request.
Ionis Pharmaceuticals (IONS): Director transaction reported. On 10/31/2025, director Joseph Loscalzo exercised a non-qualified stock option for 16,000 shares at an exercise price of $52.22 per share and sold 16,000 shares the same day. The reported sale price was a weighted average of $75.1043, with individual trades executed between $75.00 and $75.47.
The option originated from a grant exercisable since 07/03/2018 and expiring on 07/02/2027, and the director reported 0 derivative securities remaining afterward. Following these transactions, direct beneficial ownership was 36,330 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2024.
Ionis Pharmaceuticals (IONS) executive Richard S. Geary, EVP and Chief Development Officer, reported option exercises and related sales. On 10/31/2025 and 11/03/2025, he exercised non-qualified stock options at $60.89 and $56.78, then sold shares pursuant to a Rule 10b5-1 trading plan adopted on May 6, 2025. Weighted average sale prices were $75.1083 (range $75.00–$75.47) and $75.054 (range $75.00–$75.25). Following these transactions, he beneficially owns 59,657 shares directly.
Ionis Pharmaceuticals (IONS) filed an 8-K/A adding Item 1.01 and attaching an Advisory Services Agreement with Dr. Richard Geary, who will advise the company following his retirement in January 2026. The agreement runs from January 16, 2026 through February 13, 2027 and can be terminated by either party with at least 15 days’ written notice.
Dr. Geary will receive a total fee of $300,000, plus $400 per hour for any hours above 16 in a week, up to six additional hours. Total payments will not exceed $450,000 without prior written authorization.
Ionis Pharmaceuticals (IONS) filed its Q3 2025 10‑Q, reporting higher revenue and continued investment in launches and late‑stage programs. Total revenue was $156.7 million, up from $133.8 million a year ago, driven by $31.8 million in TRYNGOLZA product sales and higher royalties. Net loss was $128.6 million versus $140.5 million in the prior‑year quarter as operating expenses rose with commercialization activity.
For the nine months, revenue reached $740.4 million versus $478.6 million, reflecting recognition of the $278 million sapablursen license to Ono in Q2 and growing commercial and royalty streams. The company launched DAWNZERA in the U.S. in August 2025 following FDA approval, and continues to co‑commercialize WAINUA, with SPINRAZA royalties contributing $55.9 million in the quarter. Cash and cash equivalents were $338.3 million and short‑term investments were $1.90 billion as of September 30, 2025. Convertible notes outstanding include $575.0 million (1.75% due June 2028) and $632.5 million (0% due April 2026). Shares outstanding were 161,974,393 as of October 23, 2025.
Ionis Pharmaceuticals (IONS) furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The press release (Exhibit 99.1) presents both GAAP and non-GAAP figures. Non-GAAP results exclude non-cash compensation expense related to equity awards and the related tax effects, which the company says helps users assess and compare performance and project future results and cash flows. The information and exhibit are furnished under Item 2.02 and are not deemed filed under Section 18 of the Exchange Act.